Andrea Sitlinger, MD, Duke University Cancer Institute
Articles
Advice for Community Oncologists on Treating HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Treatments for Relapsed/Refractory HCL in Pipeline
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
The Role of CD22-targeted Immunotoxins in HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Landscape Change in the Treatment of Relapsed/Refractory HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Historical Treatment for Relapsed/Refractory HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Combination First-line Therapy in Hairy Cell Leukemia
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Determining When to Treat and First-Line Therapy for HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Differential Diagnosis and Molecular Tests in Identifying HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Signs and Tests for Diagnosis and Prognosis of HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Molecular Genetic Changes for Hairy Cell Leukemia
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Introduction and Epidemiology of Hairy Cell Leukemia
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
